We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Pharnext | EU:ALPHA | Euronext | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.0208 | -17.36% | 0.099 | 0.098 | 0.1095 | 0.115 | 0.092 | 0.1072 | 329,806 | 16:40:00 |
Regulatory News:
Pharnext SA (FR0011191287 - ALPHA) (Paris:ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drug combinations based on big data genomics and artificial intelligence, today announced its upcoming participation in five international scientific conferences in June and July 2018 throughout Europe and the United States.
Pharnext will share the latest scientific and clinical data regarding PXT3003, a drug candidate which is currently being evaluated in an ongoing international pivotal Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A. Pharnext will also illustrate the benefits of its disruptive R&D approach PLEOTHERAPY™ in developing drug combinations, and discuss the Company’s Phase 2 trial of PXT864 for the treatment of Alzheimer’s disease.
The company will attend the following events:
European Academy of Neurology (EAN) congressJune 16-18, 2018 in Lisbon, Portugal
Two ePosters (oral communications)
#EPR1170A multicenter, double-blind, placebo-controlled, pivotal phase III study (PLEO-CMT) of a fixed combination of baclofen, naltrexone and sorbitol (PXT3003) for Charcot-Marie-Tooth Disease Type 1A (CMT1A).
Presenter: Dr René Goedkoop, MD, Chief Medical Officer, Pharnext, France Room Session EPR122 / Screen B12 Date/Time June 16, 2018, 13:30 - 14:15 CEST #EPR1007Double-blind argument for a synergistic therapeutic effect of a fixed low-dose combination of acamprosate and baclofen in Alzheimer's disease.
Presenter: Dr René Goedkoop, MD, Chief Medical Officer, Pharnext, France Room Session EPR101 / Screen A1 Date/Time June 16, 2018, 13:30 - 14:15 CESTInternational Congress on Neuromuscular Diseases (ICNMD)July 6-10, 2018 in Vienna, Austria
Two Posters
#545 Baclofen, naltrexone and sorbitol all contribute to the efficacy of PXT3003 in CMT1A rats. Authors T. Prukop et al. Room Mezzanine Floor Gallery and Foyers Date/Time July 8, 2018, 5:15pm - 6:30pm CEST #728Baclofen, naltrexone and sorbitol all contribute to PXT3003-induced myelination in CMT1A DRG co-cultures.
Authors N. Cholet et al. Room Session Room 1 Date/Time July 8, 2018, 5:15pm - 6:30pm CESTInnovations and State of the Art In Dementia Research meeting (ISADR)July 16-18, 2081 in Valencia, Spain
Two Oral Communications
Cmax-based synergistic therapeutic effect on cognitive disability in mild Alzheimer’s disease after 36 weeks treatment with baclofen and acamprosate.
Presenter: Prof Jacques Touchon, MD, PhD, Faculteì de Meìdecine de Montpellier, France Date/Time July 16, 2018, 11:35am - 11:55am CEST A potential tri-therapy for Alzheimer’s disease. Presenter: Dr Rodolphe Hajj, PhD, Chief Pharmacology Officer, Pharnext, France Date/Time July 16, 2018, 12:55pm - 1:15pm CESTPeripheral Nerve Society (PNS) congressJuly 22-25, 2018 in Baltimore, US
One Oral Communication
Status of the Pivotal Phase III Study of PXT3003 for Charcot-Marie-Tooth Type 1A disease (CMT1A).
Presenter: Dr René Goedkoop, MD, Chief Medical Officer, Pharnext, France Date/Time July 23, 2018, 2.45pm - 3.00pm ESTFour Posters
#20 Baclofen, naltrexone and sorbitol all contribute to the efficacy of PXT3003 in CMT1A rats. Authors R. Hajj et al. Session Session 1 Date/Time July 22, 2018 #45Status of the Pivotal Phase III Study of PXT3003 for Charcot-Marie-Tooth Type 1A disease(CMT1A)
Authors R. Goedkoop et al. Session Session 2 Date/Time July 23, 2018 #85Synergy of baclofen, naltrexone and sorbitol (PXT3003) in Charcot-Marie-Tooth Type 1A (CMT1A)
Authors J. Laffaire et al Session Session 2 Date/Time July 23, 2018 #1Baclofen, naltrexone and sorbitol all contribute to PXT3003-induced myelination in CMT1A DRG co-cultures
Authors R. Hajj et al. Session Session 3 Date/Time July 24, 2018Alzheimer's Association International Conference (AAIC)July 22-26, 2018 in Chicago, US
Two Posters
#P1-061Double-blind argument for a synergistic therapeutic effect of a fixed low-dose combination of acamprosate and baclofen in Alzheimer’s Disease
Authors J-M Orgogozo et al Session Session P1-01 / Hall F1 Date/Time July 22, 2018, 9:30am - 4:15pm EST #P3-042PXT864 combination restores cognitive deficits of Alzheimer’s mice, even in animals with advanced disease that lost responsiveness to donepezil.
Authors A. Brureau et al. Session Session P3-02, Hall F1 Date/Time July 24, 2018, 9:30am - 4:15pm ESTIf you are interested in meeting the Pharnext team during either of these events or if you need more information about Pharnext’s participation, please send an email to contact@pharnext.com
About PharnextPharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for orphan and common neurodegenerative diseases that currently lack curative and/or disease-modifying treatments. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. The results of this trial are expected in the second half of 2018. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext has developed a new drug discovery paradigm based on big genomic data and artificial intelligence: PLEOTHERAPY™. The Company identifies and develops synergic combinations of drugs called PLEODRUG™ offering several key advantages: efficacy, safety and robust intellectual property. The Company was founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics and is supported by a world-class scientific team.
Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN code: FR0011191287).For more information, visit http://www.pharnext.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20180611005795/en/
PharnextXavier Paoli, +33 (0)1 41 09 22 30Chief Commercial Officercontact@pharnext.comorFinancial Communication (France)ActifinStéphane Ruiz, +33 (0)1 56 88 11 15sruiz@actifin.frorInvestor Relations (U.S.)Stern Investor Relations, Inc.Matthew Shinseki, +1 212 362 1200matthew@sternir.comorInvestor Relations (Europe)MC Services AGAnne Hennecke, +49 211 529252 22anne.hennecke@mc-services.euorMedia Relations (Europe)Ulysse CommunicationBruno Arabian, +33 (0)1 81 70 96 30barabian@ulysse-communication.comorMedia Relations (U.S.)RooneyPartnersKate L. Barrette, +1 212 223 0561kbarrette@rooneyco.com
1 Year Pharnext Chart |
1 Month Pharnext Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions